TY - JOUR
T1 - Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure
AU - Gislason, Gunnar H
AU - Rasmussen, Jeppe Nørgaard
AU - Abildstrøm, Steen Zabell
AU - Schramm, Tina K
AU - Hansen, Morten L
AU - Fosbøl, Emil L
AU - Sørensen, Rikke
AU - Folke, Fredrik
AU - Buch, Pernille
AU - Gadsbøll, Niels
AU - Rasmussen, Søren
AU - Poulsen, Henrik E
AU - Køber, Lars
AU - Madsen, Mette
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar H
AU - Rasmussen, Jeppe N
AU - Abildstrom, Steen Z
AU - Schramm, Tina K
AU - Hansen, Morten L
AU - Fosbøl, Emil L
AU - Sørensen, Rikke
AU - Folke, Fredrik
AU - Buch, Pernille
AU - Gadsbøll, Niels
AU - Rasmussen, Søren Poul Lind
AU - Poulsen, Henrik E
AU - Køber, Lars
AU - Madsen, Mette
AU - Torp-Pedersen, Christian
N1 - Keywords: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF. METHODS: We identified 107,092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models. RESULTS: A total of 36,354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60,974 (56.9%) died, and 8970 (8.4%) and 39,984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results. CONCLUSIONS: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.
AB - BACKGROUND: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF. METHODS: We identified 107,092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models. RESULTS: A total of 36,354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60,974 (56.9%) died, and 8970 (8.4%) and 39,984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results. CONCLUSIONS: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.
U2 - 10.1001/archinternmed.2008.525
DO - 10.1001/archinternmed.2008.525
M3 - Journal article
C2 - 19171810
SN - 0003-9926
VL - 169
SP - 141
EP - 149
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 2
ER -
